Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer

Giovanella, Luca; Imperiali, Mauro; Trimboli, Pierpaolo

doi:10.1038/s41598-017-07915-0

Cited by 18 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CK 19 immunostaining may be helpful in thyroid cancer diagnosis as a supplement to the classical cytological diagnosis between thyroid cancer and benign thyroid nodules [35]. The serum CK 19 fragment (CYFRA 21-1) stands out as a circulating marker in dedifferentiated thyroid cancers such as anaplastic thyroid carcinoma and poorly differentiated carcinoma [36,37]. CYFRA 21-1 expression has been investigated in blood and in papillary thyroid carcinoma cystic fluid.…”

Section: Discussionmentioning

confidence: 99%

CYFRA 21-1 in Lymph Node Fine Needle Aspiration Washout Improves Diagnostic Accuracy for Metastatic Lymph Nodes of Differentiated Thyroid Cancer

Lee

Park

Jeong

et al. 2019

Cancers

View full text Add to dashboard Cite

Fine needle aspiration cytology (FNAC) and washout thyroglobulin (Tg) measurements are the standard for evaluating a metastatic lymph node (LN) in thyroid cancer. However, patients rarely benefit from these procedures due to false results. This study aims to identify a reliable biomarker that significantly improves the diagnosis of metastatic LNs, in addition to FNAC and washout Tg. This study analyzed 130 LNs that were suspected to have metastases on thyroid ultrasonography, from June 2016 to December 2017. All subjects underwent FNAC, washout Tg measurements and a new biomarker, washout Cytokeratin fragment 21-1 (CYFRA 21-1) measurement. The final LN outcomes were confirmed by surgical histology, repeat FNAC, or follow-up image. The diagnostic values of the presence of washout CYFRA 21-1 for diagnosing metastatic LNs were evaluated according to final LN outcomes. Among the 130 LNs, 42 were metastatic lesions and 88 were benign. The washout CYFRA 21-1 levels were significantly higher in metastatic LNs than in benign LNs. In contrast to the findings of washout Tg, washout CYFRA 21-1 showed little overlap between benign and malignant LNs, and its diagnostic cutoff values were not affected by surgery. The combinations of FNAC and washout CYFRA 21-1 showed higher sensitivity (91.9%), specificity (96.5%), negative predictive value (98.8%), and diagnostic accuracy (94.2%) than FNAC with washout Tg. The combination of FNAC, washout Tg, and washout CYFRA 21-1 showed the best sensitivity (98.8%). When washout CYFRA 21-1 was applied to the discordant results that were observed between FNAC and washout Tg, 20 of 22 LNs were correctly diagnosed. Washout CYFRA 21-1 measurements in thyroid LNs provide a diagnostic modality.

show abstract

Section: Discussionmentioning

confidence: 99%

CYFRA 21-1 in Lymph Node Fine Needle Aspiration Washout Improves Diagnostic Accuracy for Metastatic Lymph Nodes of Differentiated Thyroid Cancer

Lee

Park

Jeong

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Apparently, the mechanism is still uncertain but a high level of Cyfra 21.1 showed de-differentiation leading to poor response to conventional therapy, and also promoted metastasis via EMT. Our data established an alternative role of serum Cyfra 21.1 as a de-differentiation biomarker instead of serum Tg, which is a marker of differentiated thyroid cancer [16].…”

Section: Discussionmentioning

confidence: 64%

“…Previous reports demonstrated that Cyfra 21.1 was associated with a high degree of malignancy and aggressive DTC biology [14]. Low levels of Cyfra 21.1 are associated with favorable outcome [16]. Apparently, the mechanism is still uncertain but a high level of Cyfra 21.1 showed de-differentiation leading to poor response to conventional therapy, and also promoted metastasis via EMT.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the levels did not differ between DTC groups without distant metastasis compared with those diagnosed with pulmonary metastasis [15]. However, a single study reported that a high serum Cyfra 21.1 level reflected the risk of distant spread of disease, suggesting a potential role as a tool to predict survival in DTC patients [16]. As mentioned above, the role of Cyfra 21.1 in thyroid cancer patients has yet to be established unequivocally.…”

Section: Introductionmentioning

confidence: 92%

See 1 more Smart Citation

Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis

Jeong

Lee

Yoon

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Serum Cyfra 21.1, the soluble fragment of CK19, has been used as a prognostic tumor marker in various cancers, indicating poor tumor differentiation and increased metastasis. Methods: We analyzed the serum Cyfra 21.1 level in 51 consecutive patients with thyroid cancer manifesting distant metastasis treated with prior total thyroidectomy. Serum Cyfra 21.1 levels of 26 thyroid cancer patients without metastasis and 50 healthy individuals were used for comparison. Results: Higher serum Cyfra 21.1 levels were detected in thyroid cancer patients with distant metastasis compared with healthy subjects and thyroid cancer patients without metastasis (p = 0.012). Serum Cyfra 21.1 levels were significantly increased in patients with positive BRAF V600E mutation (p = 0.019), undergoing Tyrosine Kinase Inhibitor (TKI) therapy (p = 0.008), with radioiodine-refractory status (p = 0.047), and in disease progression compared with those manifesting stable disease (p = 0.007). In progressive disease with undetectable or unmonitored thyroglobulin because of thyroglobulin antibody, serum Cyfra 21.1 was useful as a biomarker for follow-up of disease course. Conclusion: Serum Cyfra 21.1 in thyroid cancer patients might represent an alternative biomarker predicting tumor progression, especially in cases not associated with serum Tg levels.

show abstract

“…But like Tg, it may help in predicting the prognosis. 68 Besides, the higher level of it may indicate the poorly differentiated and anaplastic thyroid carcinoma, and worse prognosis of DTC.…”

Section: Blood Markersmentioning

confidence: 99%

<p>The Blood Biomarkers of Thyroid Cancer</p>

Wang¹,

Chang²,

Jia³

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: With the gradual increase in the incidence of thyroid cancer, people's attention to thyroid cancer has also gradually increased. Although the prognosis of thyroid cancer is rather mild compared to other cancers, it will still bring a heavy psychological burden on people who have been diagnosed. At present, the diagnosis of thyroid cancer mainly depends on ultrasound and percutaneous fine needle aspiration (pFNA). Due to the unsatisfactory accuracy of the diagnosis methods we use now, there are still some thyroid nodules that cannot be clearly diagnosed before surgery. Methods: In this article, we have searched for relevant research on blood markers of thyroid cancer in the past five years and categoried them into four groups. Discussion: Though we have not found a biomarker which can diagnose thyroid cancer both sensitively and specifically, we do found many substances that are related to it, and have the potential to recognize it and help the diagnosis. And perhaps combined models can do it better.

show abstract

Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer

Cited by 18 publications

References 30 publications

CYFRA 21-1 in Lymph Node Fine Needle Aspiration Washout Improves Diagnostic Accuracy for Metastatic Lymph Nodes of Differentiated Thyroid Cancer

CYFRA 21-1 in Lymph Node Fine Needle Aspiration Washout Improves Diagnostic Accuracy for Metastatic Lymph Nodes of Differentiated Thyroid Cancer

Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis

<p>The Blood Biomarkers of Thyroid Cancer</p>

Contact Info

Product

Resources

About